Health AI Central
Peer-Reviewed Publication
Oncologist2026September 17, 2026Journal Article

Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer.

Rana R McKay1, Deepak Kilari2, Binyam Yilma3, Unnati Jariwala3, Arya Ashok3, Stamatina Fragkogianni3, Jacob Mercer3, Neeraj Agarwal4, Emmanuel S Antonarakis5
1University of California San Diego, La Jolla, CA, USA.
2Medical College of Wisconsin, Milwaukee, WI, USA.
3Tempus AI, Inc., Chicago, IL, USA.
4University of Utah, Salt Lake City, UT, USA.
5University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA.
PubMed DOI

Abstract

BACKGROUND: Despite advances in metastatic androgen pathway modulation-sensitive prostate cancer (mAPMS) treatment, outcomes remain heterogeneous. Achieving a post-treatment undetectable prostate specific antigen (PSA) is a strong prognostic marker. We aimed to identify genomic and transcriptomic determinants of PSA response in a real-world clinical-genomic cohort. PATIENTS AND METHODS: Patients…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.